Cancer Neoantigen Peptide Vaccines: 2026 Clinical Advances

The neoantigen vaccine field has produced its most compelling clinical signal to date in melanoma, with 3-year KEYNOTE-942 follow-up data showing durable recurrence-free survival benefit from the mRNA-4157/pembrolizumab combination. The translation of this signal to other tumor types, particularly MSS colorectal cancer, faces genuine biological barriers that 2026 trial data are beginning to quantify. Organizations in peptide research and tracking industry trends should understand the clinical evidence base, manufacturing constraints, and the role of AI in neoantigen prediction.

mRNA-4157/V940: Three-Year KEYNOTE-942 Data

Moderna's mRNA-4157 (V940) in combination with pembrolizumab (Keytruda) has generated the most clinically significant neoantigen vaccine data to date. KEYNOTE-942 was a Phase IIb randomized trial in resected Stage III-IV melanoma patients, testing mRNA-4157 plus pembrolizumab versus pembrolizumab alone as adjuvant therapy. The primary endpoint was recurrence-free survival (RFS).

The original 18-month data, reported in 2023, showed a 44% reduction in risk of recurrence or death (HR 0.56, p=0.0003) in the combination arm. The 3-year follow-up data, presented at ASCO 2025, deepened this signal substantially. At 3 years, recurrence-free survival was 74% in the combination arm versus 56% in the pembrolizumab-alone arm, an absolute difference of 18 percentage points that is both clinically meaningful and statistically robust.

The durability of response at 3 years is particularly important. In adjuvant oncology, it is well established that some treatment effects that appear promising at 12-18 months attenuate at longer follow-up as late recurrences occur. The persistence of the 18-percentage-point absolute RFS difference at 3 years suggests that mRNA-4157 is producing durable T-cell immunity rather than simply delaying recurrence that eventually catches up.

Phase III KEYNOTE-A26, a fully powered, randomized trial comparing mRNA-4157 plus pembrolizumab versus pembrolizumab alone in resected high-risk melanoma, is currently enrolling. The primary endpoint is RFS with overall survival as a key secondary endpoint. Enrollment timelines suggest Phase III results could be available by 2028, with potential NDA filing in 2029. More information on the clinical trial program is available through NCI and the NIH clinical trials registry.

Gritstone GRANITE: MSS-CRC Results

Gritstone Bio's GRANITE program targets microsatellite stable colorectal cancer (MSS-CRC), one of the most immunotherapy-resistant solid tumor types. Unlike microsatellite instable (MSI-H) CRC, which responds well to checkpoint inhibitors due to its high tumor mutational burden, MSS-CRC has a low mutational burden and an immunologically cold tumor microenvironment that does not respond to existing immunotherapy approaches.

GRANITE is a heterologous prime-boost neoantigen vaccine: an adenovirus-based prime delivering neoantigen peptide-encoding sequences followed by a self-amplifying RNA boost. The approach aims to generate neoantigen-specific T-cell responses in a tumor type where such responses have historically been minimal.

Phase II results from GRANITE in second-line MSS-CRC showed 3 objective responses among 23 evaluable patients (13% ORR). While 13% ORR is modest by oncology standards, it is notable in MSS-CRC where the benchmark from checkpoint inhibitor monotherapy is near zero. The responding patients showed evidence of neoantigen-specific CD8+ T-cell expansion in peripheral blood, providing immunological confirmation that the vaccine was generating the intended immune response.

Whether 13% ORR translates to meaningful clinical benefit in randomized trials is an open question. Gritstone is designing additional clinical work based on the GRANITE data, with particular attention to patient selection criteria that might identify the immunological characteristics predicting response.

NEC AI Neoantigen Prediction: 2.3x Improvement Over NetMHCpan

A critical technical bottleneck in neoantigen vaccine development is neoantigen selection, identifying which of a patient's thousands of tumor mutations produce peptides that will be presented by that patient's MHC molecules and recognized by T cells. Poor neoantigen selection results in vaccines that generate immune responses against peptides not actually presented by tumor cells, wasting the manufacturing investment and the patient's immunological resources on non-productive targets.

NEC Corporation's NeoAntigen Prediction Engine uses a deep learning architecture trained on HLA-peptide binding and immunogenicity data to predict which mutant peptides will be effectively presented by a patient's specific HLA alleles. Validation studies comparing NEC's prediction engine to the widely used NetMHCpan algorithm showed a 2.3x improvement in the positive predictive value of neoantigen selection, meaning that peptides selected by NEC's algorithm were 2.3 times more likely to be actually presented by tumor cells and immunogenic than those selected by the legacy algorithm.

This improvement in prediction accuracy has direct implications for vaccine design and manufacturing economics. If neoantigen selection accuracy improves, fewer neoantigens need to be included in each vaccine to reliably engage tumor-reactive T cells, which reduces manufacturing cost and turnaround time. Improved selection also reduces the number of vaccines generated that fail to produce meaningful T-cell responses, a patient-level failure that is both clinically costly and financially wasteful.

Manufacturing Cost and Turnaround Time

Personalized neoantigen vaccines are manufactured individually for each patient, using tumor sequencing and neoantigen prediction to select the patient's unique peptide payload. This manufacturing model is fundamentally different from conventional pharmaceutical production and creates unusual cost and logistics challenges.

Current manufacturing cost estimates for personalized peptide neoantigen vaccines range from $18,000 to $45,000 per patient, depending on the number of peptides included, the synthesis scale, the quality testing required, and the manufacturing organization. This cost range is before the cost of the companion checkpoint inhibitor (pembrolizumab WAC: approximately $11,000 per infusion), administration, and monitoring.

The manufacturing turnaround time, from tumor biopsy to ready-to-administer vaccine, is currently 4-8 weeks for most programs. This window must fit within the clinical management of the patient: the vaccine must be ready before the window of adjuvant or neoadjuvant therapy closes. Manufacturing delays that push beyond the clinical window can mean the vaccine is not administered at the optimal time point in the disease course, potentially reducing its efficacy.

Scalability is the other manufacturing challenge. If neoantigen vaccines receive FDA approval and enter commercial use even in a subset of cancer indications, manufacturing infrastructure will need to expand dramatically from current capacity levels. The NCI and industry consortia are working on manufacturing standardization frameworks that could reduce per-patient costs over time through economies of scale and process optimization. These industry trends in manufacturing scalability will substantially determine whether neoantigen vaccines become a widely accessible cancer treatment or remain limited to well-resourced academic medical center networks. The workforce solutions implications for CMC, analytical, and clinical operations teams supporting neoantigen vaccine programs are significant and growing.